Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Fast Money traders Dan Nathan and Tim Seymour reveal their 2024 acronyms
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Fast Money ‘Fast Money’ traders Dan Nathan and Tim Seymour reveal their 2024 acronym stock groups they are watching. 05:11 Mon, Jan 8 20246:17 PM EST
Coinbase CEO Brian Armstrong on SEC ETF decision: We’ll see new pools of capital come into bitcoin
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Coinbase CEO Brian Armstrong joins ‘Squawk Box’ to discuss the SEC’s approval of bitcoin ETFs, what it means for the investing community, what’s next for crypto, and more. 08:32 Thu, Jan 11 20248:45 AM EST
How Am I Doing? Joseph, 55
Fifty-five year old Joseph is single and wants to retire at age 62 and move closer to his family in Michigan. Is he on track to meet his goal? Suze takes a look.
GM’s McNeill on EV market: Headlines are disconnected from the data
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Jon McNeill, GM board member and former Tesla president, joins ‘Squawk on the Street’ to discuss why growth is not slowing in the electric vehicle market, if McNeill shares the popular worries for the EV market, and more.
New York Fed President John Williams: Inflation is easing but policy still needs to be tight
CNBC’s Steve Liesman joins ‘Closing Bell’ to report on Fed Williams recent comments.
There’s still a lot of free cash flow for Boeing, says Gabelli Funds’ Tony Bancroft
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dean Crutchfield, CEO of the crisis management firm Crutchfield + Partners, and Tony Bancroft, portfolio manager at Gabelli Funds, join ‘Power Lunch’ to discuss the continued market fallout for Boeing following a plane’s parts malfunction.
